• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quick Take: Pegbelfermin (BMS-986036), a PEGylated Fibroblast Growth Factor 21 Analogue, in Patients with Non-Alcoholic Steatohepatitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2a Trial

byKyle HoffmanandAliya Ramjaun
December 23, 2018
in Chronic Disease, Endocrinology, Gastroenterology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Non-alcoholic steatohepatitis (NASH), the most common chronic liver disease in the United States, puts patients at increased risk of developing cirrhosis and hepatocellular carcinoma. Patients with NASH are also at an increased risk of experiencing cardiovascular events and overall mortality. Pegbelfermin (BMS-986036) is a PEGylated human fibroblast growth factor 21 (FGF21) that has been previously shown to improve metabolic markers, such as insulin sensitivity and serum adiponectin concentration in obese individuals with type 2 diabetes. This multicenter, randomized, double-blind phase 2a trial aimed to investigate the safety and efficacy of pegbelfermin. Patients between the ages of 21 and 75 with biopsy-proven NASH and a hepatic fat fraction of at least 10% (n=75) were randomized to receive 16 weeks of 10 mg of pegbelfermin once a day, 20 mg of pegbelfermin once a week, or placebo once a day. Researchers found that the absolute hepatic fat fraction was significantly decreased in the two groups receiving pegbelfermin as compared to placebo, with a mean change of -6.8% in the group receiving pegbelfermin daily versus the -1.3% mean change seen in the placebo group (p=0.0004). In the group receiving weekly pegbelfermin, a significant difference was also noted with a mean change of -5.2% in the intervention group compared to -1.3% in the placebo group (p=0.008). No deaths, treatment-related serious adverse events, or discontinuations due to adverse events were observed. Investigators therefore concluded that treatment with 16 weeks of subcutaneous pegbelfermin was well tolerated and resulted in a significant reduction in hepatic fat fraction in patients with NASH.

Click to read the study in Lancet

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Characterization of the increased incidence of alcohol-associated hepatitis noted in Ontario, Canada in past two decades

Probiotic use may decrease risk factors for metabolic syndrome

High levels of serum hypersensitive C-reactive protein are associated with non-alcoholic fatty liver

Tags: metabolic syndromeNASHpegbelfermin
Previous Post

Quick Take: Oral Ixazomib Maintenance Following Autologous Stem Cell Transplantation (TOURMALINE-MM3): A Double-Blind, Randomised, Placebo-Controlled Phase 3 Trial

Next Post

Quick Take: Association of Screening and Treatment for Preoperative Asymptomatic Bacteriuria with Postoperative Outcomes Among US Veterans

RelatedReports

Increasing survival rates for patients with acute liver failure
Chronic Disease

Characterization of the increased incidence of alcohol-associated hepatitis noted in Ontario, Canada in past two decades

February 11, 2025
Gender conformity influences use of laxatives and muscle-building products
Cardiology

Probiotic use may decrease risk factors for metabolic syndrome

January 14, 2025
Chronic Disease

High levels of serum hypersensitive C-reactive protein are associated with non-alcoholic fatty liver

December 3, 2024
Type I diabetes not associated with early menopause [OVADIA study]
Endocrinology

Risk factors for diabetes in people with HIV

October 7, 2024
Next Post
Normal renal ultrasound only rules out high grade vesicoureteral reflux in infants

Quick Take: Association of Screening and Treatment for Preoperative Asymptomatic Bacteriuria with Postoperative Outcomes Among US Veterans

Eating in the absence of hunger linked to toddler obesity

Significant unreimbursed costs linked to care coordination for medically complex children

Intensive rehabilitation not superior to traditional therapy for arm function after stroke

Risk of lifetime stroke exhibits notable geographic variation

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.